On November 15, 2026, the U.S. FDA declined to approve Summit Therapeutics and Akeso's lung cancer drug ivonescimab. Although ivonescimab plus chemotherapy reduced disease progression risk by 48%, the FDA determined that overall survival data failed to achieve statistical significance. Licensed from Akeso in 2022 for up to $5 billion, the dual-action drug faces existing market competition from Johnson & Johnson's Rybrevant regimen and AstraZeneca's Tagrisso.
FDA rejection and survival data
- ▪The FDA concluded ivonescimab's progression-free survival benefit alone did not support a favorable benefit-risk profile as Summit Therapeutics' late-stage primary analysis failed to demonstrate a statistically significant overall survival benefit
- ▪On November 15, 2026, the U.S. Food and Drug Administration issued a complete response letter declining to approve Summit Therapeutics and Akeso's lung cancer drug ivonescimab for patients whose cancer progressed after earlier therapies
Ivonescimab global Licensing Rights
- ▪Summit Therapeutics acquired development rights for ivonescimab across North America, Europe, and Japan from China-based Akeso in 2022 under an agreement worth up to $5 billion
- ▪China-based Akeso retained the rights to ivonescimab in China and other markets under its 2022 licensing agreement with Summit Therapeutics
Alternative approved lung cancer treatments
- ▪Approved alternative therapies for post-progression lung cancer include Johnson & Johnson's chemotherapy-free combination treatment incorporating Rybrevant
- ▪AstraZeneca's Tagrisso represents another regulatory-approved treatment option for patients with advanced lung cancer following initial treatment failure
Story comments
Loading comments…